Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing
Abstract Pharmacogenomics has the potential to inform drug dosing and selection, reduce adverse events, and improve medication efficacy; however, provider knowledge of pharmacogenomic testing varies across provider types and specialties. Given that many actionable pharmacogenomic genes are implicate...
Main Authors: | Callan Russell, MaryAnn Campion, Megan E. Grove, Kelly Matsuda, Teri E. Klein, Euan Ashley, Hetanshi Naik, Matthew T. Wheeler, Stuart A. Scott |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13737 |
Similar Items
-
P179: The ClinGen Pharmacogenomics Working Group: Developing frameworks for evaluating pharmacogenomic gene validity and actionability
by: Li Gong, et al.
Published: (2024-01-01) -
P525: Medical genetics providers require training and institutional support to integrate pharmacogenomic testing
by: John Imbrie, et al.
Published: (2024-01-01) -
Digital Health Applications for Pharmacogenetic Clinical Trials
by: Hetanshi Naik, et al.
Published: (2020-10-01) -
P178: The ClinGen Pharmacogenomics Working Group: Developing a framework for gene-drug response clinical validity
by: Li Gong, et al.
Published: (2023-01-01) -
Pharmacist’s attitudes and knowledge of pharmacogenomics and the factors that may predict future engagement
by: Megan E. Hundertmark, et al.
Published: (2020-09-01)